Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

UFPT vs INSP: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

UFPT Wins Head-to-Head Institutional Verdict (4–2 across 6 Pillars · 7–3 Matrix Metrics)

UFPT Overall Winner 6-Pillar Tally: UFPT 4 – 2 INSP Matrix Metrics: UFPT 7 – 3 INSP

As of Nov 16, 2026, UFP Technologies Inc (UFPT) is the stronger overall head-to-head candidate over Inspire Medical Systems, Inc. (INSP) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). UFPT carries a Unified Composite Score of 42.6/100 (HOLD) at $298.54 (24.7x Forward P/E, 15.4% operating margin), whereas INSP carries 56.6/100 (HOLD) at $59.12 (39.5x Forward P/E, 4.5% operating margin).

  • Composite vs. Pillar Nuance: While INSP currently prints a higher short-term Unified Composite Score (56.6/100 HOLD vs. UFPT 42.6/100 HOLD), UFPT captures the overall institutional head-to-head verdict (7–3 matrix metrics and 4–2 across the 6 pillars) due to superior fundamental profitability (15.4% vs. 4.5% operating margin) and revenue trajectory (+11.6% vs. -7.9% YoY).
  • Technical & Structure Timing Caution: UFPT is currently in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 49.8); meanwhile INSP trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 33.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About UFPT vs INSP
UFPT NASDAQ Head-to-Head Winner
UFP Technologies Inc
Surgical & Medical Instruments & Apparatus
$298.54
-2.14% 1D
Market Cap $2.4B
TTM Revenue $650M
Forward P/E 24.7x
Beta / 30D Vol 1.64β · 77% Vol
Unified Composite Score
42.6 / 100 HOLD
Tech 25.0 Fund 37.0 Flow 50.0 Mom 40.0
Weinstein Technical Phase Distribution · Trim / tighten stop
Price near a flattening SMA50 (slope -1.1%) with fading momentum, RSI 50
RSI-14: 49.8 · SMA20: $298.97 · SMA50: $293.17
INSP NYSE
Inspire Medical Systems, Inc.
Surgical & Medical Instruments & Apparatus
$59.12
-3.24% 1D
Market Cap $1.8B
TTM Revenue $881M
Forward P/E 39.5x
Beta / 30D Vol 0.74β · 48% Vol
Unified Composite Score
56.6 / 100 HOLD
Tech 33.0 Fund 56.0 Flow 55.0 Mom 64.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 34
RSI-14: 33.7 · SMA20: $66.74 · SMA50: $68.88

6-Pillar Scorecard Institutional Category Breakdown (UFPT 4 – 2 INSP)

Columns: Metric · UFPT · INSP
1. Valuation Multiples UFPT
Forward P/E 24.7x 39.5x
Trailing P/E 31.2x 18.2x
PEG Ratio 3.80x N/M
EV / Revenue 3.6x 1.8x
2. Growth & Scale UFPT
Revenue Growth (YoY) +11.6% -7.9%
Earnings Growth (YoY) +25.1% +308.4%
TTM Revenue (USD) $650M $881M
Market Cap $2.4B $1.8B
3. Profitability & Quality UFPT
Gross Margin 28.9% 86.2%
Operating Margin 15.4% 4.5%
Net Profit Margin 11.8% 11.4%
Return on Equity (ROE) 17.2% 13.5%
4. Balance Sheet & Cash Flow UFPT
Cash Generation (TTM) $120M EBITDA $98M
Cash Flow Margin 18.5% EBITDA Mgn 11.1%
Net Cash / Leverage $62.70 Book/Sh · 17.2% ROE $162M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning INSP
Options Structure Phase UNCLASSIFIED CONSOLIDATION
Current IV / %ile 42.3% (3rd %ile) 50.3% (8th %ile)
Put/Call OI Skew N/A 0.24x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Distribution DISTRIBUTION · Neutral
6. R&D & Supply-Chain Moat INSP
OpEx & R&D Intensity 13.5% of Rev ($88M) 81.7% of Rev ($720M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Scale & Operating Efficiency Moat Cyclical / Execution-Driven Positioning
Supply-Chain Role Medical Devices Operator Medical Devices Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: UFPT (7) vs INSP (3)
Institutional Metric UFPT INSP Criterion Row Edge
Market Capitalization
Scale
$2.4B $1.8B Larger Scale UFPT
Trailing P/E Ratio
Valuation
31.2x 18.2x Lower Multiple INSP
Forward P/E Ratio
Valuation
24.7x 39.5x Lower Multiple UFPT
Revenue Growth (YoY)
Growth
+11.6% -7.9% Higher Growth UFPT
Operating Margin (TTM)
Profitability
15.4% 4.5% Higher Margin UFPT
Net Profit Margin
Profitability
11.8% 11.4% Higher Margin UFPT
Return on Equity (ROE)
Capital Efficiency
17.2% 13.5% Higher ROE UFPT
52-Week Range Position
Momentum
74% ($174–$342) 19% ($39–$147) Stronger Trend UFPT
Beta / 30D Volatility
Risk Regime
1.64β · 77% Vol 0.74β · 48% Vol Lower Realized Risk INSP
Unified Institutional Score
Composite Signal
42.6 / 100 (HOLD) 56.6 / 100 (HOLD) Higher Composite INSP
Trailing 12M Revenue (USD)
Operating Scale
$650M $881M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
28.9% 86.2% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
3.80x PEG · 3.6x EV/Rev N/M PEG · 1.8x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$120M EBITDA ($62.70 Book/Sh · 17.2% ROE) $98M ($162M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon UFPT +16.42 pp
UFPT: +2.36% · INSP: -14.06%
3M Horizon INSP +7.95 pp
UFPT: -4.92% · INSP: +3.03%
6M Horizon INSP +3.89 pp
UFPT: +37.44% · INSP: +41.33%
1Y Horizon UFPT +59.29 pp
UFPT: +27.42% · INSP: -31.87%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on UFPT vs INSP. Trailing 12-month operating profitability (UFPT 15.4% vs INSP 4.5%) and valuation multiples (UFPT 24.7x vs INSP 39.5x Forward P/E) are benchmarked directly in Pillar 4 below.

UFPT ADR TTM Benchmark FX-Normalized USD
TTM Revenue$650M
Gross Margin28.9%
Op. Margin15.4%
ROE / Fwd P/E17.2% · 24.7x
INSP ADR TTM Benchmark FX-Normalized USD
TTM Revenue$881M
Gross Margin86.2%
Op. Margin4.5%
ROE / Fwd P/E13.5% · 39.5x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
UFPT UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 42.3%
IV Percentile 3rd %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact UFPT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
INSP CONSOLIDATION
44d in phase · OBV DISTRIBUTION
Current IV 50.3%
IV Percentile 8th %ile
Put/Call OI Skew 0.24x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow DISTRIBUTION
Exact INSP Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
UFPT Moat Profile Scale & Operating Efficiency Moat
Medical Devices Operator
Competes within the Medical Devices value chain with $2.4B market capitalization and 15.4% operating margin.
OpEx & R&D Reinvestment 13.5% of Rev ($88M)
90D Engineering Disclosures 0 Published
INSP Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $1.8B market capitalization and 4.5% operating margin.
OpEx & R&D Reinvestment 81.7% of Rev ($720M)
90D Engineering Disclosures 0 Published

Investor FAQ UFPT vs INSP Key Questions & Quantitative Answers

As of Nov 16, 2026, UFP Technologies Inc (UFPT) is the stronger overall head-to-head candidate over Inspire Medical Systems, Inc. (INSP) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). UFPT carries a Unified Composite Score of 42.6/100 (HOLD) at $298.54 (24.7x Forward P/E, 15.4% operating margin), whereas INSP carries 56.6/100 (HOLD) at $59.12 (39.5x Forward P/E, 4.5% operating margin). Composite vs. Pillar Nuance: While INSP currently prints a higher short-term Unified Composite Score (56.6/100 HOLD vs. UFPT 42.6/100 HOLD), UFPT captures the overall institutional head-to-head verdict (7–3 matrix metrics and 4–2 across the 6 pillars) due to superior fundamental profitability (15.4% vs. 4.5% operating margin) and revenue trajectory (+11.6% vs. -7.9% YoY). Technical & Structure Timing Caution: UFPT is currently in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 49.8); meanwhile INSP trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 33.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

UFPT leads the Growth & Scale pillar: UFPT posts +11.6% YoY revenue growth and +25.1% YoY earnings growth on $650M TTM revenue (28.9% gross margin, 15.4% operating margin), compared with INSP at -7.9% YoY revenue growth and +308.4% YoY earnings growth on $881M TTM revenue (86.2% gross margin, 4.5% operating margin). On trailing 12-month operating scale, UFPT generates $650M in USD-normalized revenue versus $881M for INSP. In operating R&D and SG&A reinvestment, UFPT deploys 13.5% of Rev ($88M) (0 90-day corporate R&D disclosures) versus 81.7% of Rev ($720M) (0 disclosures) for INSP.

UFPT screens cheaper on headline valuation multiples. UFPT trades at 24.7x Forward P/E, 31.2x Trailing P/E, 3.80x PEG, and 3.6x EV/Revenue (18.5% EBITDA margin), whereas INSP trades at 39.5x Forward P/E, 18.2x Trailing P/E, N/M PEG, and 1.8x EV/Revenue (11.1% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against UFPT (17.2% ROE) versus INSP (13.5% ROE) capital efficiency.

In options market volatility and institutional positioning, UFPT carries 42.3% implied volatility (3rd %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.64β · 77% Vol realized risk). By comparison, INSP carries 50.3% implied volatility (8th %ile, Compressed (<25th %ile)), a 0.24x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.74β · 48% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.